Page 34 - Solid Tumors News Today

Kura Oncology (NASDAQ:KURA – Get Rating) had its target price cut by analysts at Stifel Nicolaus from $25.00 to $24.00 in a research report issued on Thursday, The Fly reports. Stifel Nicolaus’ price objective indicates a potential upside of 100.50% from the stock’s current price. A number of other equities research analysts also recently commented […]

A phase 3 trial comparing QL1206, a denosumab biosimilar, to the reference agent has returned results demonstrating the efficacy, safety, and pharmacokinetic equivalency of the biosimilar to the reference agent.

Singapore's Health Sciences Authority (HSA) has approved QINLOCK® (ripretinib) for the treatment of patients with 4th line GIST QINLOCK significantly reduced the risk of disease progression or death by 85% and showed clinically meaningful overall survival in the INVICTUS Phase 3 Study1,2 SINGAPORE, May 8, 2023 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is pleased to...

/PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is pleased to announce that a new therapy to treat rare...

Jayesh Desai, MBBS, FRACP, shares data from a phase IB study investigating KRAS G12C inhibitor GDC-6036, or divarasib, in combination with cetuximab for the treatment of patients with colorectal cancer.

-Total Revenues of $520 Million in 1Q23, Including Net Product Sales of $469 Million- -PADCEV® Granted FDA Accelerated Approval in Combination with KEYTRUDA® as First-Line Treatment for... | April 27, 2023

/PRNewswire/ -- Strata Oncology, Inc. ("Strata"), a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced...

Efficacy and safety data for BeiGene’s therapy shows positive results for individuals with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

Kura Oncology, Inc. (NASDAQ:KURA – Get Rating) – Research analysts at HC Wainwright lifted their FY2025 earnings estimates for Kura Oncology in a research report issued on Monday, April 17th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($2.04) per share for the year, up from their prior forecast […]

The combination of tislelizumab plus chemotherapy elicited a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy plus placebo in patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.